Sermorelin
Geref / GHRH 1-29 / GRF 1-29
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid native GHRH sequence. Originally FDA-approved as Geref for pediatric growth hormone deficiency diagnostics and treatment, it remains one of the most widely compounded peptides for age-related GH decline. Its mechanism preserves natural pulsatile GH release patterns and hypothalamic-pituitary feedback loops, distinguishing it from exogenous growth hormone administration.
Mécanisme d'action
Synthetic analog of the first 29 amino acids of endogenous GHRH. Stimulates pituitary somatotrophs to release GH in a physiologic, pulsatile pattern. Preserves negative feedback through somatostatin, preventing supraphysiologic GH levels.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols use 200-500mcg daily via subcutaneous injection at bedtime to coincide with natural nocturnal GH surge. Continuous use for 3-6 months. Often combined with a GHRP.
Notes de recherche
Clinical Research Status
Sermorelin was FDA-approved in 1997 as Geref Diagnostic (IV) and Geref (subcutaneous) for pediatric GH deficiency but was voluntarily discontinued by EMD Serono in 2008 for commercial reasons, not safety concerns. It remains available through compounding pharmacies under physician supervision and is one of the most prescribed peptides in anti-aging medicine. Phase IV post-marketing data accumulated over a decade of clinical use established a strong safety profile.
Key Published Findings
Clinical trials demonstrated significant increases in IGF-1 levels, lean body mass, and decreased visceral adiposity in GH-deficient patients. A 2012 study in the Journal of Clinical Endocrinology & Metabolism showed improved sleep quality and increased slow-wave sleep duration. Research indicates sermorelin preserves the natural GH pulsatile secretion pattern, unlike exogenous GH which suppresses endogenous production. Long-term studies showed sustained benefits over 6-12 months without tachyphylaxis.
Safety Profile
Sermorelin has one of the most established safety profiles among GH-related peptides due to its decade of FDA-approved clinical use. Common side effects are limited to injection site reactions, facial flushing, and transient headache. Because it works through the hypothalamic-pituitary axis, overdose risk is self-limiting as the body's negative feedback mechanisms remain intact. No significant adverse cardiovascular or oncological signals emerged during post-marketing surveillance.
Drug Interactions & Contraindications
Contraindicated in patients with active malignancy due to theoretical concerns about GH-mediated tumor growth promotion. Glucocorticoids may blunt the GH response to sermorelin, and concurrent use with somatostatin analogs (octreotide) will antagonize its effects. Patients on thyroid hormone replacement should have levels monitored as GH can increase T4 to T3 conversion. Caution advised in patients with obesity as adiposity reduces GH response to GHRH stimulation.
Comparison to Related Compounds
Unlike CJC-1295, sermorelin has a shorter half-life (10-20 minutes) requiring more frequent dosing but producing more physiologic GH pulses. Compared to tesamorelin (the only currently FDA-approved GHRH analog, for HIV lipodystrophy), sermorelin is less potent but more widely accessible through compounding. It is considered gentler than ipamorelin/CJC-1295 combinations and is often recommended as a starting point for GH optimization. Relative to exogenous GH, sermorelin maintains feedback regulation and does not suppress endogenous production.
Community Observations
Users commonly report improved sleep quality within the first 1-2 weeks, with body composition changes becoming apparent at 3-6 months. The peptide is typically dosed at 200-300 mcg subcutaneously before bedtime to synergize with natural nocturnal GH secretion. Some practitioners cycle sermorelin (5 days on, 2 days off) though clinical data supporting cycling protocols is limited. It is frequently combined with ipamorelin (a GHSP) for synergistic GH release through complementary receptor pathways.
Moitié de vie
~10-20 minutes
Réconstitution
Bacteriostatic water (BAC)
Conservation
Lyophilisé
Refrigerate 2-8C up to 18 months.
Réconstitué
Refrigerate 2-8C. Use within 14 days.
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que Sermorelin ?
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-amino acid native GHRH sequence. Originally FDA-approved as Geref for pediatric growth hormone deficiency diagnostics and treatment, it remains one of the most widely compounded peptides for age-related GH decline. Its mechanism preserves natural pulsatile GH release patterns and hypothalamic-pituitary feedback loops, distinguishing it from exogenous growth hormone administration.
Comment agit Sermorelin ?
Synthetic analog of the first 29 amino acids of endogenous GHRH. Stimulates pituitary somatotrophs to release GH in a physiologic, pulsatile pattern. Preserves negative feedback through somatostatin, preventing supraphysiologic GH levels.
Quel est le statut réglementaire de Sermorelin aux États-Unis ?
Research chemical (formerly FDA-approved)
Quelle est la demi-vie de Sermorelin ?
~10-20 minutes
Sous quels autres noms Sermorelin est-il connu ?
Geref, GHRH 1-29, GRF 1-29
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète